Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377484 | 0.82 | MET (0.64) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377478 | 0.82 | MAPK14 (0.51) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377519 | 0.82 | MAPK14 (0.52) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377508 | 0.81 | MET (0.63) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377510 | 0.80 | MET (0.58) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2286491 | 0.80 | MET (0.70) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377524 | 0.78 | MAPK14 (0.48) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377504 | 0.78 | MAPK14 (0.47) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377528 | 0.77 | MAPT (0.50) | METMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12377485 | 0.75 | MGAM (0.40) | METMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | MET 8/4885MAPK14 818/4885MAPK13 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.